Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Richard Dodel

Showing results (211-220 of 250) with videos related to

Pageof 25
Sort By:
Alzheimer'S & Dementia (Amsterdam, Netherlands)|February 25, 2025
A network perspective on cognition in individuals with Parkinson's diseaseDaniel Scharfenberg, Elke Kalbe, Monika Balzer-Geldsetzer, et al.
NPJ Parkinson'S Disease|April 6, 2026
Temporal dynamics of cognitive functioning in people with Parkinson's diseaseDaniel Scharfenberg, Elke Kalbe, Anja Ophey, et al.
International Journal of Methods in Psychiatric Research|April 19, 2017
Psychometric properties of the apathy evaluation scale in patients with Parkinson's diseaseUlrike Lueken, Ricarda Evens, Monika Balzer-Geldsetzer, et al.
The American Journal of Geriatric Psychiatry : Official Journal of the American Association for Geriatric Psychiatry|August 8, 2018
Psychometric Properties of an Abbreviated Version of the Apathy Evaluation Scale for Parkinson Disease (AES-12PD)Yuliya Stankevich, Ulrike Lueken, Monika Balzer-Geldsetzer, et al.
Plos One|July 14, 2015
Measuring Compounds in Exhaled Air to Detect Alzheimer's Disease and Parkinson's DiseaseJan-Philipp Bach, Maike Gold, David Mengel, et al.
Parkinsonism & Related Disorders|August 21, 2021
A new CERAD total score with equally weighted z-scores and additional executive and non-amnestic "CERAD-Plus" tests enhances cognitive diagnosis in patients with Parkinson's disease: Evidence from the LANDSCAPE studyRobert Lillig, Anja Ophey, Jörg B Schulz, et al.
Journal of Neurology|July 1, 2024
Mid- and late-life lifestyle activities as main drivers of general and domain-specific cognitive reserve in individuals with Parkinson's disease: cross-sectional and longitudinal evidence from the LANDSCAPE studyAnja Ophey, Kathrin Wirtz, Steffen Wolfsgruber, et al.
Journal of Parkinson'S Disease|June 23, 2020
Optimizing Treatment in Undertreated Late-Stage Parkinsonism: A Pragmatic Randomized TrialAdrianus L A J Hommel, Marjan J Meinders, Nico J Weerkamp, et al.
The Lancet. Neurology|February 5, 2013
Intravenous immunoglobulin for treatment of mild-to-moderate Alzheimer's disease: a phase 2, randomised, double-blind, placebo-controlled, dose-finding trialRichard Dodel, Axel Rominger, Peter Bartenstein, et al.
European Neuropsychopharmacology : the Journal of the European College of Neuropsychopharmacology|October 5, 2010
Costs of illness and care in Parkinson's disease: an evaluation in six countriesSonja von Campenhausen, Yaroslav Winter, Antonio Rodrigues e Silva, et al.
Pageof 25

Showing results (211-220 of 250) with videos related to

Sort By:
Pageof 25
Alzheimer'S & Dementia (Amsterdam, Netherlands)|February 25, 2025
A network perspective on cognition in individuals with Parkinson's diseaseDaniel Scharfenberg, Elke Kalbe, Monika Balzer-Geldsetzer, et al.
NPJ Parkinson'S Disease|April 6, 2026
Temporal dynamics of cognitive functioning in people with Parkinson's diseaseDaniel Scharfenberg, Elke Kalbe, Anja Ophey, et al.
International Journal of Methods in Psychiatric Research|April 19, 2017
Psychometric properties of the apathy evaluation scale in patients with Parkinson's diseaseUlrike Lueken, Ricarda Evens, Monika Balzer-Geldsetzer, et al.
The American Journal of Geriatric Psychiatry : Official Journal of the American Association for Geriatric Psychiatry|August 8, 2018
Psychometric Properties of an Abbreviated Version of the Apathy Evaluation Scale for Parkinson Disease (AES-12PD)Yuliya Stankevich, Ulrike Lueken, Monika Balzer-Geldsetzer, et al.
Plos One|July 14, 2015
Measuring Compounds in Exhaled Air to Detect Alzheimer's Disease and Parkinson's DiseaseJan-Philipp Bach, Maike Gold, David Mengel, et al.
Parkinsonism & Related Disorders|August 21, 2021
A new CERAD total score with equally weighted z-scores and additional executive and non-amnestic "CERAD-Plus" tests enhances cognitive diagnosis in patients with Parkinson's disease: Evidence from the LANDSCAPE studyRobert Lillig, Anja Ophey, Jörg B Schulz, et al.
Journal of Neurology|July 1, 2024
Mid- and late-life lifestyle activities as main drivers of general and domain-specific cognitive reserve in individuals with Parkinson's disease: cross-sectional and longitudinal evidence from the LANDSCAPE studyAnja Ophey, Kathrin Wirtz, Steffen Wolfsgruber, et al.
Journal of Parkinson'S Disease|June 23, 2020
Optimizing Treatment in Undertreated Late-Stage Parkinsonism: A Pragmatic Randomized TrialAdrianus L A J Hommel, Marjan J Meinders, Nico J Weerkamp, et al.
The Lancet. Neurology|February 5, 2013
Intravenous immunoglobulin for treatment of mild-to-moderate Alzheimer's disease: a phase 2, randomised, double-blind, placebo-controlled, dose-finding trialRichard Dodel, Axel Rominger, Peter Bartenstein, et al.
European Neuropsychopharmacology : the Journal of the European College of Neuropsychopharmacology|October 5, 2010
Costs of illness and care in Parkinson's disease: an evaluation in six countriesSonja von Campenhausen, Yaroslav Winter, Antonio Rodrigues e Silva, et al.
Pageof 25